



Gerd R Pape

Kontakt

Gerd R Pape

Publikationen (10)

Kronenberger B, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Buggisch P, Gerlach T, Hinrichsen H, Herrmann E, Berg T, Zeuzem S. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. *European journal of gastroenterology & hepatology* 2007; 19:639-46.

Lucas M, Santantonio T, Fidler S, Thimme R, Haberstroh A, Baumert T, Klenerman P, Diepolder H, Nitschko H, Obermeier M, Phillips R, Scriba T, Semmo N, Day C, Weber J, Schraut W, Pape G, Zachoval R, Ulsenheimer A, Pfafferot K, Heeg M, Gaudieri S, Grüner N, Rauch A, Gerlach T, Jung M. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. *PloS one* 2007; 2:e649.

Berg T, Alshuth U, Martus P, Spengler U, Klinker H, Kallinowski B, Schmidt W, Pape G, Rasenack J, Goeser T, Buggisch P, Gerlach T, Heintges T, Sarrazin C, Nasser S, von Wagner M, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 2006; 130:1086-97.

Ulsenheimer A, Pape G, Zachoval R, Schirren C, Heeg M, Schraut W, Santantonio T, Backmund M, Wächtler M, Gruener N, Jung M, Gerlach T, Diepolder H. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. *Hepatology (Baltimore, Md.)* 2005; 41:643-51.

Steinmann D, Blum H, Liang T, Inchauspé G, Patel A, Maertens G, Jacobs D, Depla E, Pape G, Gerlach T, Adah M, Schürmann P, Gissler B, Barth H, Baumert T. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. *Journal of virology* 2004; 78:9030-40.

Gerlach T, Backmund M, Waechter M, Schirren C, Schraut W, Ulsenheimer A, Jung M, Gruener N, Zachoval R, Diepolder H, Pape G. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology* 2003; 125:80-8.

Berg T, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Herrmann E, Buggisch P, Gerlach T, Hinrichsen H, Kronenberger B, Zeuzem S. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. *Hepatology (Baltimore, Md.)* 2003; 37:1359-67.

Ulsenheimer A, Gerlach T, Gruener N, Jung M, Schirren C, Schraut W, Zachoval R, Pape G, Diepolder H. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. *Hepatology (Baltimore, Md.)* 2003; 37:1189-98.

Gruener N, Backmund M, Wächtler M, Hoffmann R, Schirren C, Diepolder H, Gerlach T, Ulsenheimer A, Jung M, Pape G. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. *Journal of hepatology* 2002; 37:866-9.

Jung M, Zeuzem S, Trojan J, Whitehead E, Birtles E, Bailey J, Page M, Schirren C, Diepolder H, Gerlach T, Schraut W, Zachoval R, Grüner N, Pape G. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. *Vaccine* 2002; 20:3598-612.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch